South San Francisco, California-based biotech startup Maze Therapeutics is set to receive a $150M cash and equity infusion from Sanofi.
In addition, the business signed a global licensing deal with Sanofi for its glycogen synthase 1 (GYS1) program and lead asset MZE001. Maze could potentially receive $600M through the licensing deal, subject to development, regulatory, and sales milestones.
- The GYS1 program is aimed at treating Pompe disease "by limiting disease-causing glycogen accumulation," per Maze.
- Maze intends to use the incoming funds to advance the treatment of two candidates for chronic kidney disease.
- 15% of Sanofi's current product pipeline consists of therapeutics for Pompe disease.